SI1648925T1 - Biciklična peptidna kontrastna sredstva - Google Patents
Biciklična peptidna kontrastna sredstvaInfo
- Publication number
- SI1648925T1 SI1648925T1 SI200431293T SI200431293T SI1648925T1 SI 1648925 T1 SI1648925 T1 SI 1648925T1 SI 200431293 T SI200431293 T SI 200431293T SI 200431293 T SI200431293 T SI 200431293T SI 1648925 T1 SI1648925 T1 SI 1648925T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imaging agents
- bicyclic peptide
- peptide imaging
- compounds
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317815.9A GB0317815D0 (en) | 2003-07-30 | 2003-07-30 | Imaging agents |
| PCT/GB2004/003150 WO2005012335A1 (en) | 2003-07-30 | 2004-07-21 | Imaging agents |
| EP04743485A EP1648925B1 (en) | 2003-07-30 | 2004-07-21 | Bicyclic peptide imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1648925T1 true SI1648925T1 (sl) | 2010-01-29 |
Family
ID=27799463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200431293T SI1648925T1 (sl) | 2003-07-30 | 2004-07-21 | Biciklična peptidna kontrastna sredstva |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7410943B2 (sl) |
| EP (1) | EP1648925B1 (sl) |
| JP (1) | JP4625002B2 (sl) |
| KR (1) | KR101153529B1 (sl) |
| CN (1) | CN1829735B (sl) |
| AT (1) | ATE442379T1 (sl) |
| BR (1) | BRPI0412986A (sl) |
| CA (1) | CA2533321C (sl) |
| CY (1) | CY1109522T1 (sl) |
| DE (1) | DE602004023092D1 (sl) |
| DK (1) | DK1648925T3 (sl) |
| ES (1) | ES2332722T3 (sl) |
| GB (1) | GB0317815D0 (sl) |
| HK (1) | HK1097278A1 (sl) |
| HU (1) | HUP0600230A3 (sl) |
| IL (1) | IL173029A0 (sl) |
| MX (1) | MXPA06001090A (sl) |
| NO (1) | NO20060825L (sl) |
| NZ (1) | NZ544583A (sl) |
| PL (2) | PL1648925T3 (sl) |
| PT (1) | PT1648925E (sl) |
| RU (2) | RU2355702C2 (sl) |
| SI (1) | SI1648925T1 (sl) |
| WO (1) | WO2005012335A1 (sl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL207834B1 (pl) * | 2001-07-10 | 2011-02-28 | Ge Healthcare As | Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
| GB0206750D0 (en) * | 2002-03-22 | 2002-05-01 | Amersham Plc | Radiofluorination methods |
| NO20033115D0 (no) * | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
| CN102895666B (zh) * | 2003-12-16 | 2015-08-19 | 尼克塔治疗公司 | 化学改性的小分子 |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| AU2005254915B2 (en) * | 2004-06-16 | 2011-10-13 | Ge Healthcare As | Peptide-based compounds |
| GB0420344D0 (en) * | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
| ES2358745T3 (es) | 2004-11-22 | 2011-05-13 | Ge Healthcare As | Agentes de contraste para señalar matriz extracelular. |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
| EP2010227A2 (en) | 2006-04-20 | 2009-01-07 | Hammersmith Imanet Limited | Radiofluorinated compounds and their preparation |
| US7960506B2 (en) | 2006-12-14 | 2011-06-14 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
| CN109627287A (zh) | 2007-02-23 | 2019-04-16 | 爱勒让治疗公司 | 三唑大环系统 |
| WO2008121767A2 (en) | 2007-03-28 | 2008-10-09 | President And Fellows Of Harvard College | Stitched polypeptides |
| GB0722650D0 (en) * | 2007-11-19 | 2007-12-27 | Ge Healthcare Ltd | Novel imaging method |
| EP2240171B1 (en) * | 2008-01-09 | 2014-08-13 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase IX |
| ES2402850T3 (es) * | 2008-02-28 | 2013-05-09 | Ge Healthcare Limited | Síntesis de un resto de PEG-6 a partir de productos químicos comerciales de bajo coste |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| JP2012504147A (ja) * | 2008-09-29 | 2012-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびＡ−２−α受容体作動薬の組み合わせ |
| JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
| GB0910013D0 (en) * | 2009-06-10 | 2009-07-22 | Ge Healthcare Ltd | PET imaging of fibogenesis |
| JP2013505300A (ja) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| US20120229804A1 (en) | 2009-12-21 | 2012-09-13 | Medi-Physics, Inc. | Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f- ion |
| RU2582678C2 (ru) | 2010-08-13 | 2016-04-27 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
| CU24317B1 (es) | 2010-09-30 | 2018-02-08 | Astrazeneca Ab | Conjugado de naloxol-peg cristalino |
| FR2967671A1 (fr) * | 2010-11-24 | 2012-05-25 | Pf Medicament | Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses |
| TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| KR102570210B1 (ko) | 2014-09-24 | 2023-08-23 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 제제 |
| CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| GB201511036D0 (en) | 2015-06-23 | 2015-08-05 | Guy S And St Thomas Hospital Nhs Foundation Trust | Imaging method |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| GB201621864D0 (en) * | 2016-12-21 | 2017-02-01 | Ge Healthcare Ltd | Solid phase conditioning |
| CN113000001A (zh) * | 2021-03-22 | 2021-06-22 | 洛阳海惠新材料股份有限公司 | 一种用于制备pbat的增粘连体反应器 |
| CN113750923A (zh) * | 2021-08-30 | 2021-12-07 | 桐昆集团浙江恒腾差别化纤维有限公司 | 一种酯化反应回收系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930703024A (ko) * | 1991-02-08 | 1993-11-29 | 리챠드 티. 딘 | 영상용 테크네튬-99m표지폴리펩티드 |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| CN1230441C (zh) * | 2000-04-12 | 2005-12-07 | 安盛药业有限公司 | 结合整联蛋白的肽衍生物 |
| AU2001288847A1 (en) * | 2000-09-07 | 2002-03-22 | Biosyntema Inc. | Conformationally constrained labeled peptides for imaging and therapy |
| IL141276A0 (en) * | 2001-02-05 | 2002-03-10 | Peptor Ltd | Backbone cyclized radiolabelled somatostatin analogs |
| PL207834B1 (pl) * | 2001-07-10 | 2011-02-28 | Ge Healthcare As | Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
-
2003
- 2003-07-30 GB GBGB0317815.9A patent/GB0317815D0/en not_active Ceased
-
2004
- 2004-07-21 HU HU0600230A patent/HUP0600230A3/hu unknown
- 2004-07-21 AT AT04743485T patent/ATE442379T1/de active
- 2004-07-21 BR BRPI0412986-5A patent/BRPI0412986A/pt not_active IP Right Cessation
- 2004-07-21 US US10/566,487 patent/US7410943B2/en not_active Expired - Fee Related
- 2004-07-21 RU RU2006102324/04A patent/RU2355702C2/ru not_active IP Right Cessation
- 2004-07-21 MX MXPA06001090A patent/MXPA06001090A/es active IP Right Grant
- 2004-07-21 DE DE602004023092T patent/DE602004023092D1/de active Active
- 2004-07-21 ES ES04743485T patent/ES2332722T3/es active Active
- 2004-07-21 CA CA2533321A patent/CA2533321C/en not_active Expired - Fee Related
- 2004-07-21 PL PL04743485T patent/PL1648925T3/pl unknown
- 2004-07-21 EP EP04743485A patent/EP1648925B1/en not_active Not-in-force
- 2004-07-21 NZ NZ544583A patent/NZ544583A/xx not_active IP Right Cessation
- 2004-07-21 DK DK04743485T patent/DK1648925T3/da active
- 2004-07-21 WO PCT/GB2004/003150 patent/WO2005012335A1/en active Application Filing
- 2004-07-21 SI SI200431293T patent/SI1648925T1/sl unknown
- 2004-07-21 PL PL379705A patent/PL210122B1/pl not_active IP Right Cessation
- 2004-07-21 JP JP2006521646A patent/JP4625002B2/ja not_active Expired - Fee Related
- 2004-07-21 PT PT04743485T patent/PT1648925E/pt unknown
- 2004-07-21 KR KR1020067001968A patent/KR101153529B1/ko not_active IP Right Cessation
- 2004-07-21 CN CN2004800220449A patent/CN1829735B/zh not_active Expired - Fee Related
-
2006
- 2006-01-09 IL IL173029A patent/IL173029A0/en unknown
- 2006-02-21 NO NO20060825A patent/NO20060825L/no not_active Application Discontinuation
-
2007
- 2007-03-01 HK HK07102321.9A patent/HK1097278A1/xx not_active IP Right Cessation
-
2008
- 2008-06-18 US US12/141,123 patent/US7811551B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 RU RU2009105640/04A patent/RU2009105640A/ru not_active Application Discontinuation
- 2009-12-01 CY CY20091101253T patent/CY1109522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1648925T1 (sl) | Biciklična peptidna kontrastna sredstva | |
| AU9245601A (en) | Peptide-based compounds | |
| MXPA04000173A (es) | Compuestos basados en peptidos. | |
| EP1641423A4 (en) | BENZODIAZEPINE-CGRP Receptor Antagonists | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| BR0008688A (pt) | Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 | |
| AP1503A (en) | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | |
| EP1606286A4 (en) | BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS | |
| MY161834A (en) | Substituted diazepan compounds as orexin receptor antagonists | |
| MX2009012579A (es) | Antagonistas piridil piperidina del receptor de orexina. | |
| TW200510429A (en) | Heterocyclic MCHR1 antagonists | |
| IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
| NO20022655L (no) | <Beta>-2-adrenerge reseptoragonister | |
| EP1605936A4 (en) | ARYL SPIROHYDANTINE CGRP RECEPTOR ANTAGONISTS | |
| TW200505903A (en) | CGRP receptor antagonists | |
| AU5068301A (en) | Peptide-based compounds | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| DE60230683D1 (de) | 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| MXPA05011233A (es) | Vectores peptidicos. | |
| EP0648762A3 (en) | Bicyclic compounds as excitatory amino acid receptor antagonists | |
| PL2101826T3 (pl) | Znakowane izotopowo związki na bazie peptydów i ich zastosowania |